NCT07554690Not yet recruiting
Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration
Photobiomodulation Laser in Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
This study evaluates whether a low-energy laser treatment called photobiomodulation (PBM) can improve visual function and retinal structure in patients with age-related macular degeneration (AMD) who have reticular pseudodrusen. PBM is a non-invasive therapy that uses specific wavelengths of light to stimulate cellular activity and reduce inflammation without causing tissue damage. Participants will be randomly assigned to receive either active PBM treatment or a sham (inactive) treatment. The study will assess changes in visual performance under low-light conditions and retinal structure over a 12-month period. The goal is to determine whether PBM can slow disease progression and improve visual function in patients with early stages of AMD.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 67 (estimated)
- First submitted
- 21 Apr 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Fondazione G.B. Bietti, IRCCS
- Diseases
- Macular degeneration
- NCT number
- NCT07554690
What you commit to
- Study type: Interventional
- Planned participants: 67
- From 1 Oct 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any previous treatment for age-related macular degeneration, except for antioxidant supplementation
- Use of phototoxic medications (including certain antibiotics or chemotherapeutics) during PBM treatment
- Any intraocular surgery within 3 months prior to enrollment in the study eye
- Previous thermal laser treatment in the macular region of the study eye
- Previous therapeutic radiation to the ocular region or face
Other illness
- History of uveitis (idiopathic or autoimmune)
- History of vitrectomy, filtering surgery, corneal transplantation, or retinal detachment in the study eye
Other
- Presence of geographic atrophy
- Evidence of macular neovascularization
- Media opacities that may interfere with retinal imaging assessments
- Any ocular or systemic treatment known to be toxic to the retina or optic nerve
- Neovascular glaucoma
- Glaucoma due to congenital anomalies
- Glaucoma secondary to active uveitis
- Women of childbearing potential not using effective contraception during the study treatment period
Who the study is looking for
- Age ≥ 50 years
- Diagnosis of reticular pseudodrusen secondary to age-related macular degeneration in the study eye
- Best-corrected visual acuity (BCVA) between 20/20 and 20/400 (inclusive)
- Ability and willingness to comply with study procedures and visits
- Written informed consent obtained prior to any study procedures
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Fondazione G.B.Bietti c/o Ospedale Britannico Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.